Cystic Fibrosis May Be Linked To Obstructive Pulmonary Disease
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Cystic Fibrosis May Be Linked To Obstructive Pulmonary Disease

LONDON, ENGLAND -- June 26, 1998 -- Cystic fibrosis is a common genetic disorder that often causes premature death. It is characterised by lung disease that leads to airway obstruction. People heterozygous (one dominant gene, one recessive) for certain gene mutations associated with cystic fibrosis may have increased susceptibility to the development of obstructive pulmonary disease.

Dr, Morten Dahl and colleagues from Denmark looked for an association between the common gene mutation F508 that causes cystic fibrosis and the risk of developing asthma. They report their findings in this week's issue of The Lancet.

The investigators enrolled 9,141 people aged 20 years or older from the general adult population of Copenhagen. They measured the largest volume of air the participants could breathe out in one second and the total amount of air they could breathe out in relation to the amount inhaled. They asked participants about any external factors, such as smoking or exposure to industrial fumes, that could have influenced the development of obstructive pulmonary disease. They also tested blood samples to find out whether participants were heterozygous carriers of the cystic-fibrosis mutation.

Significantly more people (nine percent) who were carriers of the F508 mutation had asthma symptoms compared with non-carriers. The risk of having asthma was increased two-fold if the heterozygous mutation was carried. Among those who already had airway obstruction, the capacity of the lungs was decreased and the ability to exhale impaired in people heterozygous for the cystic-fibrosis mutation compared with non-carriers.

"Cystic fibrosis F508 heterozygosity may be over-represented among people with asthma," the researchers write. "Individuals heterozygous for F508 may account for up to two percent of people with asthma in the general population."

They believe that even though the prevalence of asthma varies from country to country, their results could be applicable to many countries of the world.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities